首页> 美国卫生研究院文献>Journal of Hematology Oncology >Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel docetaxel or erlotinib in patients with advanced solid tumors

【2h】

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel docetaxel or erlotinib in patients with advanced solid tumors

机译：口服AKT抑制剂MK-2206联合卡铂/紫杉醇多西紫杉醇或厄洛替尼用于晚期实体瘤的1期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundInhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.

机译：背景技术用MK-2206抑制AKT已证明与抗癌药具有协同作用。这项1期研究评估了MK-2206的MTD，DLT，PK和功效，并结合了细胞毒性和靶向疗法。

著录项

期刊名称 Journal of Hematology Oncology
作者
L Rhoda Molife; Li Yan; Joanna Vitfell-Rasmussen; Adriane M Zernhelt; Daniel M Sullivan; Philippe A Cassier; Eric Chen; Andrea Biondo; Ernestina Tetteh; Lillian L Siu; Amita Patnaik; Kyriakos P Papadopoulos; Johann S de Bono; Anthony W Tolcher; Susan Minton;
展开▼
作者单位

展开▼
年(卷),期 2014(7),-1
年度 2014
页码 1
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;血液学检验;
关键词
MK-2206 AKT inhibitor Protein serine-threonine kinase Phase 1 Chemotherapy Combination therapy Solid tumors;

机译：MK-2206;AKT抑制剂;蛋白丝氨酸-苏氨酸激酶;1期;化学疗法;联合疗法;实体瘤;

相似文献

外文文献
中文文献
专利

1. 多西紫杉醇联合卡铂与氟尿嘧啶联合卡铂治疗局部晚期鼻咽癌近期疗效的比较 [J] . 吕星, 郭翔, 洪明晃, 癌症（英文版） . 2010,第002期
2. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors [J] . L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, Journal of Hematology and Oncology . 2014,第1期

机译：口服AKT抑制剂MK-2206加卡铂/紫杉醇，多西紫杉醇或厄洛替尼用于晚期实体瘤患者的1期试验
3. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors [J] . A Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Investigational new drugs. . 2019,第1期

机译：PEVONEDISTAT，NEDD8活化酶抑制剂的相位IB研究，与多西紫杉醇，卡铂和紫杉醇，或吉西他滨组合，在先进的实体瘤患者中
4. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. [J] . Yap TA, Yan L, Patnaik A, Journal of Clinical Oncology . 2011,第35期

机译：口服pan-AKT抑制剂MK-2206在晚期实体瘤患者中的首次人体临床试验。
5. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
6. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
7. Phase Ib study of pevonedistat a NEDD8-activating enzyme inhibitor in combination with docetaxel carboplatin and paclitaxel or gemcitabine in patients with advanced solid tumors [O] . A Craig Lockhart, Todd M. Bauer, Charu Aggarwal, -1

机译：在晚期实体瘤患者中NED8活化酶抑制剂培维酮他汀与多西他赛卡铂和紫杉醇或吉西他滨合用的Ib期研究
8. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors [O] . L Molife, Li Yan, Joanna Vitfell-Rasmussen, 2014

机译：口服AKT抑制剂MK-2206联合卡铂/紫杉醇，多西紫杉醇或厄洛替尼用于晚期实体瘤的1期试验

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel docetaxel or erlotinib in patients with advanced solid tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅